Inhalants in 2026: The Quietest Drug Story of the Year — and the One With the Most Preventable Damage

The substance class with the loudest news cycle in 2026 is nicotine. The substance class with the most genuinely new clinical evidence is alcohol. The substance class with the most preventable damage — by an order of magnitude — is inhalants.

This isn’t a story about youth experimentation alone. The patients showing up in emergency departments with weakness, numbness, and unsteady gait this year are increasingly working-age adults who have been using whippits — small canisters of nitrous oxide marketed as cream chargers — daily for weeks or months. The pattern is consistent enough that 2026 case reports are emerging from EDs across the U.S., the U.K., and Europe with what the literature now describes as a recognizable clinical syndrome.

The biology, in one paragraph

Nitrous oxide inactivates vitamin B12 by oxidizing its cobalt center. B12 is required for myelin maintenance — the insulating sheath around your nerves. When chronic N2O use depletes functional B12, the dorsal columns of the spinal cord begin to demyelinate. This is called subacute combined degeneration. The first symptoms are usually tingling and numbness in the hands and feet, then unsteady walking, then progressive weakness. MRI shows a characteristic “inverted V” or “dumbbell” signal in the cervical or thoracic cord. Multiple 2026 case reports in Frontiers in Psychiatry, MDPI Reports, and the Western Journal of Emergency Medicine document the same arc — and emphasize that emergency-department clinicians, who don’t typically screen for whippet use, are missing the diagnosis for weeks at a time.

If caught early, B12 replacement plus cessation of N2O exposure can produce substantial recovery. If caught late, some of the damage is permanent. The case reports note patients in their 20s and 30s who lose ambulation entirely; one 2026 report describes a 50-year-old female presenting with daily use of “20 whippits × 3–4 weeks” — gait instability, lower-extremity sensory loss, slurred speech, and MRI confirmation of cervicothoracic centromedullary myelopathy.

The policy picture, just as quickly

Nitrous oxide–related deaths in the U.S. rose from 23 in 2010 to 156 in 2023, per the data the FDA cites in its consumer advisory. The advisory itself warns against recreational inhalation of any flavor of nitrous oxide in any size canister, tank, or charger, citing nerve damage, cardiac arrest, stroke, spinal cord injury, brain damage, and death.

State legislatures are starting to move. Tennessee’s Nitrous Oxide Abuse Prevention and Retail Sales Prohibition Act (SB1843) becomes effective July 1, 2026 — banning recreational retail sale at $500 per product for first violations, with higher fines for repeats, and carving out exemptions for medical, dental, and food-related use. California cities and counties — Orange County and Newport Beach among them — have already enacted local recreational-sale misdemeanor ordinances. Federal action remains limited; nitrous oxide is not a scheduled substance under the Controlled Substances Act.

The “Galaxy Gas” multidistrict litigation, which consolidates personal-injury cases against retailers and brands that marketed flavored canisters explicitly to recreational users, remains active in 2026. The judicial conference is ongoing, and product-liability outcomes there are likely to shape retail availability faster than state law in 2027.

Where the field actually disagrees

Most of the disagreement among clinicians and policymakers in 2026 is not about whether nitrous oxide harms users — that’s settled. It’s about whether the right policy response is criminalization of recreational sale, structured harm reduction (better labeling, B12 supplementation guidance, behind-the-counter restrictions), public-health-style education campaigns, or some combination. The harm-reduction position, articulated most clearly in Filter Magazine and by addiction-medicine clinicians, is that retail bans without education risk pushing users toward larger industrial-grade tanks where dosing is harder to control. The public-health position, articulated in Tennessee’s legislative record, is that easy retail access drives the volume problem in the first place.

Most of the disagreement among clinicians and policymakers in 2026 is not about whether nitrous oxide harms users — that’s settled.

What’s not in dispute: people using whippits daily need a clinician informed about B12 status. A serum B12 level alone can miss the problem; functional markers (methylmalonic acid and homocysteine) are more sensitive, and ED clinicians who recognize the pattern are increasingly checking both.

Resources

If you or someone you know has been using whippits or nitrous oxide canisters and is experiencing tingling, numbness, weakness, balance problems, or memory changes, those are not signs of “withdrawal” — they’re potential signs of B12-deficiency myelopathy and warrant urgent medical attention. Your primary care clinician or local ED can order the right blood tests. Recovery is more likely the earlier the diagnosis is made.

For navigation help in Arizona, dial 211 or use Rize Recovery’s free find-help tool. If you’re outside Arizona, SAMHSA’s national helpline is 1-800-662-4357. If you’re in crisis, call or text 988.

---

Rize Recovery does not provide medical advice. Talk to a clinician about specific symptoms or treatment decisions.